23 October 2015 - GSK today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for a variation to expand the current therapeutic indication for Volibris (ambrisentan) to include its use in combination treatment for patients with pulmonary arterial hypertension.

For more details, go to: https://www.gsk.com/en-gb/media/press-releases/2015/gsk-receives-chmp-positive-opinion-to-expand-indication-for-volibris-in-pulmonary-arterial-hypertension/